President

GondolaBio Receives U.S. FDA Orphan Drug and Fast Track Designations for PORT-77 for the Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)

Principal Scientist / AD CMC Drug Substance

GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. They are seeking an experienced process chemist to lead process chemistry activities for a late-phase small molecule, ensuring supply chain reliability and efficiency while collaborating with external partners for process validation and regulatory filings.

President and Chief Executive Officer

Senior Vice President

12 Health Care Stocks Moving In Thursday's After-Market Session

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Xilio Therapeutics reports Q3 EPS (11c) vs (22c) last year

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

0.6666666865348816

Principal Scientist, CMC Drug Product Development

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies. The Principal Scientist, CMC Drug Product Development will oversee drug product development and manufacturing operations, collaborating with various teams to support expedited CMC development strategies.

Co-founder and SVP Head of Research

IPOs Slow to a Trickle in 2025 as Investors Grow More Discerning

Sionna Therapeutics, Inc.(NasdaqGM:SION) added to S&P Biotechnology Select Industry Index

Sionna Therapeutics Insider Sold Shares Worth $4,814,205, According to a Recent SEC Filing

5th Annual BioTech Breakthrough Awards Program Honors World’s Most Innovative Life Sciences and Biotechnology Companies

0.8333333134651184

Principal Scientist, CMC Drug Substance

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on revolutionizing treatments for cystic fibrosis (CF). They are seeking a Principal Scientist to lead drug substance development and manufacturing, providing technical expertise in synthetic methodology and process optimization.

Corp. SVP BioPharma Network

Corporate Vice President, Head of Global Supply Chain and Lifecycle Management Animal Health

Boehringer Ingelheim, Viyash Scientific enter pet healthcare pact in India

Viyash Scientific ties up with Boehringer Ingelheim to expand companion animal portfolio in India

Viyash Scientific partners with Boehringer Ingelheim to sell its companion animal products in India

FDA Approves VETMEDIN, First Drug to Delay Onset of Congestive Heart Failure in Dogs

Principal Clinical Data Scientist - Early Oncology Drug Development

Boehringer Ingelheim is a global leader in biopharmaceuticals, and they are seeking a Principal Clinical Data Scientist to support early Oncology drug development. The role involves strategic planning, execution of clinical trial designs, and analytics of clinical project data while collaborating with cross-functional teams.

SR AD/ AD, Principal Clinical Data Scientist -Early Oncology Drug Development (Remote)

President and CEO

CBO & CFO

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Top biotech deals in December 2025

Cyclerion announces strategic agreement with Medsteer

Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

Principal Scientist, Drug Substance

Akebia Therapeutics is focused on improving the lives of individuals affected by Chronic Kidney Disease. The Principal Scientist of Drug Substance will lead technical efforts in late-stage product development and process optimization for praliciguat, ensuring compliance and timely delivery of drug substance supplies for clinical activities.